HealthDay News — For adults with oral corticosteroid (OCS)-dependent severe uncontrolled asthma, tezepelumab can help to reduce OCS use, according to a study published online November 26 in The Lancet ...

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

HealthDay News — Adjunct corticosteroids probably reduce short-term mortality in adults with severe pneumonia or acute respiratory distress syndrome (ARDS), according to a review published online ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

The new recommendation allows parents to make the decision on when or if their child will receive the hepatitis B vaccine.

Jaypirca gains expanded approval; allograft approved to restore peripheral nerve function; baxdrostat to be reviewed as an add-on treatment for hypertension; treatment for a genetic eye disorder that ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

Pazdur reportedly questioned whether a new FDA program called the Commissioner’s National Priority Voucher, designed to speed reviews for drugs tied to national priorities, was transparent or even ...

HealthDay News — Millions of people rely on continuous glucose monitors to help manage diabetes. But a new alert from the Food and Drug Administration (FDA) warns that some sensors from Abbott may ...

HealthDay News — For adult patients with hereditary hemorrhagic telangiectasia (HHT), a new, allosteric, selective activin receptor-like kinase 1 inhibitor, oral engasertib, is safe and is associated ...

Omlyclo was originally approved in March 2025 in 2 single-dose prefilled syringe strengths: 75mg/0.5mL and 150mg/mL.